News AstraZeneca sells rights to cholesterol drug Crestor to Grun... AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal.
Views & Analysis How COVID-19 is changing the sales model The COVID-19 pandemic means that reps can no longer speak face-to-face with physicians and many HCPs simply don’t have the time to engage with pharma.
News Mundipharma, Grünenthal accused of kickbacks in Italy Two manufacturers of opioid analgesics – Mundipharma and Grünenthal – have been accused of paying an Italian doctor to promote use of the drugs.
News Grünenthal buys certain rights to AZ’s Nexium and Vimovo for... AstraZeneca has agreed to sell some of the rights to its drugs Nexium and Vimovo to Grünenthal for an upfront payment of $922 million.
News AZ considers options as US gout drug deal backfires Ironwood tears up licensing agreement after sales disappoint
News AZ sells migraine drug rights to Grunenthal for $300m AZ says migraine outside its strategic focus.
R&D Reuters Pharma USA 2024 – Meruno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.